浏览全部资源
扫码关注微信
- Journal Information
- Archive
- Submission
- For Reviewers
- Statement and Policies
Detection and evaluation of the signals of amlodipine and lercanidipine based on FAERS database
- ZHONGGUO YAOFANG Vol. 33, Issue 21, Pages: 2647-2653(2022)
- 作者机构：
1.重庆医科大学药学院，重庆 400016
2.中国人民解放军陆军特色医学中心药剂科，重庆 400042
3.重庆大学附属肿瘤医院肿瘤转移与个体化诊治转化研究重庆市重点实验室，重庆 400030
4.重庆大学附属肿瘤医院药学部，重庆 400030
5.重庆医科大学附属儿童医院药学部/儿童发育疾病研究教育部重点实验室/儿童发育重大疾病国家科技合作基地/儿科学重庆市重点实验室/国家儿童健康与疾病临床医学研究中心，重庆 400014
- 作者简介：
- 基金信息：
DOI：10.6039/j.issn.1001-0408.2022.21.16
CLC： R969.3;R972+4Published：15 November 2022，
Received：25 May 2022，
Revised：18 July 2022，
扫 描 看 全 文
钟贵遵,张妮,王红力等.基于FAERS数据库对氨氯地平和乐卡地平信号的检测与评价 Δ[J].中国药房,2022,33(21):2647-2653.
ZHONG Guizun,ZHANG Ni,WANG Hongli,et al.Detection and evaluation of the signals of amlodipine and lercanidipine based on FAERS database[J].ZHONGGUO YAOFANG,2022,33(21):2647-2653.
钟贵遵,张妮,王红力等.基于FAERS数据库对氨氯地平和乐卡地平信号的检测与评价 Δ[J].中国药房,2022,33(21):2647-2653. DOI： 10.6039/j.issn.1001-0408.2022.21.16.
ZHONG Guizun,ZHANG Ni,WANG Hongli,et al.Detection and evaluation of the signals of amlodipine and lercanidipine based on FAERS database[J].ZHONGGUO YAOFANG,2022,33(21):2647-2653. DOI： 10.6039/j.issn.1001-0408.2022.21.16.
摘要
目的
2
对氨氯地平和乐卡地平药物不良事件（ADE）进行信号检测并评价。
方法
2
检索美国FDA不良事件报告系统（FAERS）数据库2004年1月1日至2021年9月30日收录的“氨氯地平”和“乐卡地平”所有ADE报告，采用报告比值比法和贝叶斯可信区间递进神经网络法检测ADE信号，筛选出重点系统内的中强信号及强信号进行分析。
结果
2
从FAERS数据库中提取得到以氨氯地平、乐卡地平为怀疑药物的ADE报告各249 657、10 558份，检出氨氯地平、乐卡地平安全信号分别为62、58个。两药同时检出外周水肿、低血压、直立性低血压、低血容量性休克等中强信号，以上均为两药常见的不良反应。较为特殊的ADE如下：呼吸系统、胸及纵隔疾病系统中，氨氯地平检出非心源性肺水肿强信号，乐卡地平检出静息时呼吸困难强信号；胃肠系统中，氨氯地平检出齿龈肥大强信号；皮肤及皮下组织类疾病系统中，两药均检出“血管炎相关”的中强信号，氨氯地平检出线状IgA病中强信号，乐卡地平检出大疱性皮炎中强信号；肾脏及泌尿系统疾病系统中，两药均检出急性肾损伤安全信号（氨氯地平检出中强信号，乐卡地平检出强信号）；精神病类系统中，氨氯地平检出自杀既遂中强信号。低血压和急性肾损伤在两药报告数中均排在前2位。信息成分（IC）时间扫描图谱结果显示，2004－2021年，氨氯地平的非心源性肺水肿、自杀既遂信号IC值分别从0.76、－0.49增至4.48、1.95，置信区间分别从（－0.44，1.97）、（－1.01，0.03）缩窄至（4.24，4.72）、（1.90，2.01），提示信号稳定。
结论
2
临床使用氨氯地平和乐卡地平时，应警惕外周水肿、低血压、心律失常、肺水肿、牙龈增生、皮肤相关ADE、急性肾损伤及抑郁、自杀等风险。
Abstract
OBJECTIVE
2
To detect and evaluate the signals of amlodipine and lercanidipine-induced adverse drug events （ADE）.
METHODS
2
All ADE reports about “amlodipine” and “lercanidipine” were searched from FAERS database during Jan. 1st， 2004 to Sept. 30th， 2021. Reported odds ratio and Bayesian confidence propagation neural network were used to detect ADE signals. The moderately strong signals and strong signals in key systems were selected for analysis.
RESULTS
2
From FAERS database， 249 657 and 10 558 reports were extracted with amlodipine and lercanidipine as suspect drugs， respectively. In this study， 62 and 58 signals related to amlodipine and lercanidipine were detected respectively. At the same time， moderately strong signals of peripheral edema， hypotension， orthostatic hypotension and hypovolemic shock were detected in the two drugs， all of which were common adverse reactions of the two drugs. The special ADEs detected in this study were as follows： in the respiratory system， chest and mediastinal disease system， strong signals of non-cardiogenic pulmonary edema were detected for amlodipine， and strong signals of dyspnea at rest for lercanidipine； in gastrointestinal diseases， strong signals of gingival hypertrophy were detected only for amlodipine； in skin and subcutaneous tissue disease system， moderately strong signals related to “vasculitis” were detected for both drugs， moderately strong signals related to linear IgA disease were detected for amlodipine， and moderately strong signals related to bullous dermatitis were detected for lercanidipine； in the renal and urinary system disease system， the signals of acute renal injury were detected for both drugs（amlodipine was detected as a moderately strong signal， and lecardipine was detected as a strong signal）； in the mental system， moderately strong signals related to suicide were detected for amlodipine. Both hypotension and acute renal injury ranked in the top two in the number of reports of the two drugs. The time scan results of the information component （IC） of this study showed that the IC values of non-cardiogenic pulmonary edema and suicide completion signals of amlodipine increased from 0.76， －0.49 to 4.48 and 1.95 respectively， and the confidence intervals narrowed from （－0.44，1.97）， （－1.01，0.03） to （4.24，4.72） and （1.90，2.01） respectively during 2004 to 2021， suggesting that the signals kept stable.
CONCLUSIONS
2
The risks of peripheral edema， hypotension， arrhythmia， pulmonary edema， gingival hyperplasia， skin related ADE， acute renal injury， depression and suicide should be alert when using amlodipine and lercanidipine in clinic.
关键词
氨氯地平乐卡地平药物不良事件信号检测安全用药高血压
Keywords
lercanidipineadverse drug eventsignal detectionsafe drug usehypertension
references
POULTER N R，PRABHAKARAN D’CAULFIELD M. Hypertension[J]. Lancet，2015，386（9995）：801-812.
姚溪，裴晓婷，曲哲. 1991－2015年中国成人高血压患病率、知晓率、治疗率、控制率的变化趋势及其影响因素研究[J]. 中国全科医学，2022，25（7）：803-814.
TIWASKAR M，LANGOTE A，KASHYAP R，et al. Amlodipine in the era of new generation calcium channel blockers[J]. J Assoc Physicians India，2018，66（3）：64-69.
GRASSI G，ROBLES N R，SERAVALLE G，et al. Lercanidipine in the management of hypertension：an update[J]. J Pharmacol Pharmacother，2017，8（4）：155-165.
CHENG K H，CHENG K C，CHENG K Y，et al. Long-term outcomes of lercanidipine versus other calcium channel blockers in newly diagnosed hypertension：a nationwide cohort study[J]. Curr Med Res Opin，2017，33（6）：1111-1117.
山缨，王倩，范维琥，等. 乐卡地平治疗轻中度高血压患者的长期降压疗效和耐受性[J]. 中国新药杂志，2003，12（11）：936-938.
BECKEY C，LUNDY A，LUTFI N. Lercanidipine in the treatment of hypertension[J]. Ann Pharmacother，2007，41（3）：465-473.
USTAOĞLU G，ERDAL E，KARAŞ Z. Influence of different anti-hypertensive drugs on gingival overgrowth：a cross-sectional study in a Turkish population[J]. Oral Dis，2021，27（5）：1313-1319.
BÖHM R，HÖCKER J，CASCORBI I，et al. OpenVigil-free eyeballs on AERS pharmacovigilance data[J]. Nat Biotechnol，2012，30（2）：137-138.
HAUBEN M，ZHOU X F. Quantitative methods in pharmacovigilance：focus on signal detection[J]. Drug Saf，2003，26（3）：159-186.
BATE A. Bayesian confidence propagation neural network[J]. Drug Saf，2007，30（7）：623-625.
陈文戈，李婵娟，江静，等. 基于BCPNN法的药品不良反应信号检测与自动预警技术研究[J]. 计算机应用研究，2009，26（4）：1394-1397.
汤榕，李林贵，孙维红，等. 药品不良反应报告常用信号检测方法应用研究[J]. 中国药房，2012，23（14）：1309-1311.
马攀，龚莉，张妮，等. 基于FDA不良事件数据库对洛匹那韦/利托那韦信号的检测与分析[J]. 中国现代应用药学，2020，37（4）：406-413.
ORRE R，LANSNER A，BATE A，et al. Bayesian neural networks with confidence estimations applied to data mining[J]. Comput Stat Data Anal，2000，34（4）：473-493.
王宇，徐颖颖，张相彩，等. 钙离子拮抗剂类降压药的临床应用及不良反应[J]. 中国现代应用药学，2015，32（3）：385-390.
LI Y，FAN Y M，SUN Y Y，et al. Antihypertensive drug use and the risk of depression：a systematic review and network meta-analysis[J]. Front Pharmacol，2021，12：777987.
LINS R，HAERDEN Y，DE VRIES C. Replacement of amlodipine and lercanidipine by barnidipine：tolerability and effectiveness in a real-life study[J]. High Blood Press Cardiovasc Prev，2017，24（1）：29-36.
PRINCE M J，EBRAHIM S，ACOSTA D，et al. Hypertension prevalence，awareness，treatment and control among older people in Latin America，India and China：a 10/66 cross-sectional population-based survey[J]. J Hypertens，2012，30（1）：177-187.
JONES J，SWART A，TOMMY E，et al. Adverse drug reactions reported to a provincial public health sector pharmacovigilance programme in South Africa[J]. Suid Afrikaanse Tydskrif Vir Geneeskunde，2020，110（12）：1226-1230.
SANSANAYUDH N，WONGWIWATTHANANUKIT S，VEERAYUTHVILAI S. Comparison of changes of body water measured by using bioelectrical impedance analysis between lercanidipine and amlodipine therapy in hypertensive outpatients[J]. Chotmaihet Thangphaet，2010，93（Suppl 6）：S84-S92.
MORROW-BARNES A. Pulmonary oedema[J]. Nurs Stand，2016，30（40）：61-62.
HASSON R，MULCAHY V，TAHIR H. Amlodipine poisioning complicated with acute non-cardiogenic pulmonary oedema[J]. BMJ Case Rep，2011，2011：bcr0720114467.
FUKUDA Y，SUGIMOTO H，YAMADA Y，et al. Safety and feasibility of lung biopsy in diagnosis of acute respiratory distress syndrome：protocol for a systematic review and meta-analysis[J]. BMJ Open，2021，11（2）：e043600.
MAGDALAN J，ANTOŃCZYK A，KOWALSKI K，et al.Severe pulmonary complications of massive intoxication with calcium channel blockers and isosorbide mononitrate：a case report[J]. Przegl Lek，2004，61（4）：405-407.
DONGARI-BAGTZOGLOU A，Research，Science and Therapy Committee，American Academy of Periodonto- logy. Drug-associated gingival enlargement[J]. J Periodontol，2004，75（10）：1424-1431.
MIRONIUC-CUREU M，DUMITRIU A S，GHEORGHIU I M，et al. Gingival overgrowth as secondary effect of calcium channel blockers administration. A case report[J]. J Med Life，2014，7（2）：241-245.
TEN HOLDER S M，JOY M S，FALK R J. Cutaneous and systemic manifestations of drug-induced vasculitis[J]. Ann Pharmacother，2002，36（1）：130-147.
GRAU R G. Drug-induced vasculitis：new insights and a changing lineup of suspects[J]. Curr Rheumatol Rep，2015，17（12）：71.
LOW L，ZAHERI S，WAKELIN S. Amlodipine-induced linear IgA disease[J]. Clin Exp Dermatol，2012，37（6）：649-651.
CAO Y Y，XIANG X，SONG J，et al. Distinct effects of antihypertensives on depression in the real-world setting：a retrospective cohort study[J]. J Affect Disord，2019，259：386-391.
KOLIASTASIS L，LAMPADKIS I，MILKAS A，et al. Refractory shock from amlodipine overdose overcomed with hyperinsulinemia[J]. Cardiovasc Toxicol，2022，22（1）：63-66.
LUYCKX V A，NAICKER S. Acute kidney injury associated with the use of traditional medicines[J]. Nat Clin Pract Nephrol，2008，4（12）：664-671.
NAHA K，SURYANARAYANA J，AZIZ R A，et al. Amlodipine poisoning revisited：acidosis，acute kidney injury and acute respiratory distress syndrome[J]. Indian J Crit Care Med，2014，18（7）：467-469.
NBRIXIUS K， GROSS T， TOSSIOS P， et al. Increased vascular selectivity and prolonged pharmacological efficacy of the L-type Ca2+ channel antagonist lercanidipine in human cardiovascular tissue[J]. Clin Experim Pharmacol Physiol，2010，32（9）：708-713.
GORDIENKO D V，CLAUSEN C，GOLIGORSKY M S. Ionic currents and endothelin signaling in smooth muscle cells from rat renal resistance arteries[J]. Am J Physiol，1994，266（2 Pt 2）：F325-F341.
0
Views
0
下载量
0
CSCD
- L-PDFDownload
- WORDDownload
- Meta-XMLDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
- Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号
公网安备50010302001817 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.